The role of autophagy in hepatocellular carcinoma

International Journal of Molecular Sciences

Volumn 16, Issue 11, 2015, Pages 26629-26643

  Lee, Yoo Jin ^a   Jang, Byoung Kuk ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Autophagy; Hepatocellular carcinoma; Prognosis; Therapy; Tumor suppression; Tumorigenesis

Indexed keywords

4 AMINOBUTYRIC ACID C RECEPTOR; ACYL COENZYME A DESATURASE; AUTOPHAGY PROTEIN 5; BECLIN 1; CCAAT ENHANCER BINDING PROTEIN ALPHA; EVEROLIMUS; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MICROTUBULE ASSOCIATED PROTEIN 1; PROTEIN P28; PROTEIN SERINE THREONINE KINASE; SORAFENIB; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, MOUSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; SERINE THREONINE PROTEIN KINASE ULK1; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER; ULK1 PROTEIN, HUMAN;

ALCOHOL ABUSE; ALCOHOL METABOLISM; AUTOPHAGY; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; HEPATITIS B; HUMAN; LIGHT CHAIN; LIVER CELL CARCINOMA; LYSOSOME; NONALCOHOLIC FATTY LIVER; PH; REVIEW; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; MOUSE; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; AUTOPHAGY-RELATED PROTEIN-1 HOMOLOG; BECLIN-1; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICE; MULTIPROTEIN COMPLEXES; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84946854927     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161125984     Document Type: Review

References (131)

1. Rautou, P.E.; Mansouri, A.; Lebrec, D.; Durand, F.; Valla, D.; Moreau, R. Autophagy in liver diseases. J. Hepatol. 2010, 53, 1123-1134. [CrossRef] [PubMed]
2. Czaja, M.J. Functions of autophagy in hepatic and pancreatic physiology and disease. Gastroenterology 2011, 140, 1895-1908. [CrossRef] [PubMed]
3. Kroemer, G.; Marino, G.; Levine, B. Autophagy and the integrated stress response. Mol. Cell 2010, 40, 280-293. [CrossRef] [PubMed]
4. Mizushima, N.; Komatsu, M. Autophagy: Renovation of cells and tissues. Cell 2011, 147, 728-741. [CrossRef] [PubMed]
5. Klionsky, D.J. Autophagy: From phenomenology to molecular understanding in less than a decade. Nat. Rev. Mol. Cell Biol. 2007, 8, 931-937. [CrossRef] [PubMed]
6. Ding, W.X.; Ni, H.M.; Gao, W.; Yoshimori, T.; Stolz, D.B.; Ron, D.; Yin, X.M. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am. J. Pathol. 2007, 171, 513-524. [CrossRef] [PubMed]
7. Singh, R.; Cuervo, A.M. Autophagy in the cellular energetic balance. Cell Metab. 2011, 13, 495-504. [CrossRef] [PubMed]
8. Nixon, R.A. The role of autophagy in neurodegenerative disease. Nat. Med. 2013, 19, 983-997. [CrossRef] [PubMed]
9. Levine, B.; Mizushima, N.; Virgin, H.W. Autophagy in immunity and inflammation. Nature 2011, 469, 323-335. [CrossRef] [PubMed]
10. Choi, A.M.; Ryter, S.W.; Levine, B. Autophagy in human health and disease. N. Engl. J. Med. 2013, 368, 651-662. [CrossRef] [PubMed]
11. White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 2012, 12, 401-410. [CrossRef] [PubMed]
12. Kwanten, W.J.; Martinet, W.; Michielsen, P.P.; Francque, S.M. Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: A controversial issue. World J. Gastroenterol. 2014, 20, 7325-7338. [CrossRef] [PubMed]
13. Lozy, F.; Karantza, V. Autophagy and cancer cell metabolism. Semin. Cell Dev. Biol. 2012, 23, 395-401. [CrossRef] [PubMed]
14. Cui, J.; Gong, Z.; Shen, H.M. The role of autophagy in liver cancer: Molecular mechanisms and potential therapeutic targets. Biochim. Biophys. Acta 2013, 1836, 15-26. [CrossRef] [PubMed]
15. Bruix, J.; Sherman, M. Management of hepatocellular carcinoma: An update. Hepatology 2011, 53, 1020-1022. [CrossRef] [PubMed]
16. Forner, A.; Llovet, J.M.; Bruix, J. Hepatocellular carcinoma. Lancet 2012, 379, 1245-1255. [CrossRef]
17. Yan, J.; Zhou, Y.; Chen, D.; Li, L.; Yang, X.; You, Y.; Ling, X. Effects of mitochondrial translocation of telomerase on drug resistance in hepatocellular carcinoma cells. J. Cancer 2015, 6, 151-159. [CrossRef] [PubMed]
18. Huo, X.; Zhang, Q.; Liu, A.M.; Tang, C.; Gong, Y.; Bian, J.; Luk, J.M.; Xu, Z.; Chen, J. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncol. Rep. 2013, 29, 840-846. [PubMed]
19. Lee, Y.J.; Hah, Y.J.; Kang, Y.N.; Kang, K.J.; Hwang, J.S.; Chung, W.J.; Cho, K.B.; Park, K.S.; Kim, E.S.; Seo, H.Y.; et al. The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma. PLoS ONE 2013, 8, e81540. [CrossRef] [PubMed]
20. Qiu, D.M.; Wang, G.L.; Chen, L.; Xu, Y.Y.; He, S.; Cao, X.L.; Qin, J.; Zhou, J.M.; Zhang, Y.X.; Qun, E. The expression of beclin-1, an autophagic gene, in hepatocellular carcinoma associated with clinical pathological and prognostic significance. BMC Cancer 2014, 14. [CrossRef] [PubMed]
21. Pan, H.; Wang, Z.; Jiang, L.; Sui, X.; You, L.; Shou, J.; Jing, Z.; Xie, J.; Ge, W.; Cai, X.; et al. Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib. Sci. Rep. 2014, 4. [CrossRef] [PubMed]
22. Ding, Z.B.; Hui, B.; Shi, Y.H.; Zhou, J.; Peng, Y.F.; Gu, C.Y.; Yang, H.; Shi, G.M.; Ke, A.W.; Wang, X.Y.; et al. Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. Clin. Cancer Res. 2011, 17, 6229-6238. [CrossRef] [PubMed]
23. Yang, Z.; Klionsky, D.J. An overview of the molecular mechanism of autophagy. Curr. Top. Microbiol. Immunol. 2009, 335, 1-32. [PubMed]
24. Ezaki, J.; Matsumoto, N.; Takeda-Ezaki, M.; Komatsu, M.; Takahashi, K.; Hiraoka, Y.; Taka, H.; Fujimura, T.; Takehana, K.; Yoshida, M.; et al. Liver autophagy contributes to the maintenance of blood glucose and amino acid levels. Autophagy 2011, 7, 727-736. [CrossRef] [PubMed]
25. Singh, R.; Kaushik, S.; Wang, Y.; Xiang, Y.; Novak, I.; Komatsu, M.; Tanaka, K.; Cuervo, A.M.; Czaja, M.J. Autophagy regulates lipid metabolism. Nature 2009, 458, 1131-1135. [CrossRef] [PubMed]
26. Komatsu, M.; Waguri, S.; Ueno, T.; Iwata, J.; Murata, S.; Tanida, I.; Ezaki, J.; Mizushima, N.; Ohsumi, Y.; Uchiyama, Y.; et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J. Cell Biol. 2005, 169, 425-434. [CrossRef] [PubMed]
27. Inami, Y.; Waguri, S.; Sakamoto, A.; Kouno, T.; Nakada, K.; Hino, O.; Watanabe, S.; Ando, J.; Iwadate, M.; Yamamoto, M.; et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J. Cell Biol. 2011, 193, 275-284. [CrossRef] [PubMed]
28. Takamura, A.; Komatsu, M.; Hara, T.; Sakamoto, A.; Kishi, C.; Waguri, S.; Eishi, Y.; Hino, O.; Tanaka, K.; Mizushima, N. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011, 25, 795-800. [CrossRef] [PubMed]
29. Kim, J.; Kundu, M.; Viollet, B.; Guan, K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13, 132-141. [CrossRef] [PubMed]
30. Egan, D.F.; Shackelford, D.B.; Mihaylova, M.M.; Gelino, S.; Kohnz, R.A.; Mair, W.; Vasquez, D.S.; Joshi, A.; Gwinn, D.M.; Taylor, R.; et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011, 331, 456-461. [CrossRef] [PubMed]
31. Ichimura, Y.; Kirisako, T.; Takao, T.; Satomi, Y.; Shimonishi, Y.; Ishihara, N.; Mizushima, N.; Tanida, I.; Kominami, E.; Ohsumi, M.; et al. A ubiquitin-like system mediates protein lipidation. Nature 2000, 408, 488-492. [PubMed]
32. Kabeya, Y.; Mizushima, N.; Ueno, T.; Yamamoto, A.; Kirisako, T.; Noda, T.; Kominami, E.; Ohsumi, Y.; Yoshimori, T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000, 19, 5720-5728. [CrossRef] [PubMed]
33. Behrends, C.; Sowa, M.E.; Gygi, S.P.; Harper, J.W. Network organization of the human autophagy system. Nature 2010, 466, 68-76. [CrossRef] [PubMed]
34. Ogata, M.; Hino, S.; Saito, A.; Morikawa, K.; Kondo, S.; Kanemoto, S.; Murakami, T.; Taniguchi, M.; Tanii, I.; Yoshinaga, K.; et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol. Cell. Biol. 2006, 26, 9220-9231. [CrossRef] [PubMed]
35. Schneider, J.L.; Cuervo, A.M. Liver autophagy: Much more than just taking out the trash. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 187-200. [CrossRef] [PubMed]
36. Mizushima, N. Autophagy: Process and function. Genes Dev. 2007, 21, 2861-2873. [CrossRef] [PubMed]
37. Yin, X.M.; Ding, W.X.; Gao, W. Autophagy in the liver. Hepatology 2008, 47, 1773-1785. [CrossRef] [PubMed]
38. Kim, I.; Rodriguez-Enriquez, S.; Lemasters, J.J. Selective degradation of mitochondria by mitophagy. Arch. Biochem. Biophys. 2007, 462, 245-253. [CrossRef] [PubMed]
39. Rodriguez-Enriquez, S.; Kim, I.; Currin, R.T.; Lemasters, J.J. Tracker dyes to probe mitochondrial autophagy (mitophagy) in rat hepatocytes. Autophagy 2006, 2, 39-46. [CrossRef] [PubMed]
40. Ding, W.X. Role of autophagy in liver physiology and pathophysiology. World J. Biol. Chem. 2010, 1, 3-12. [CrossRef] [PubMed]
41. Wang, Z.; Han, W.; Sui, X.; Fang, Y.; Pan, H. Autophagy: A novel therapeutic target for hepatocarcinoma (Review). Oncol. Lett. 2014, 7, 1345-1351. [CrossRef] [PubMed]
42. Farazi, P.A.; DePinho, R.A. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat. Rev. Cancer 2006, 6, 674-687. [CrossRef] [PubMed]
43. Yang, L.; Li, P.; Fu, S.; Calay, E.S.; Hotamisligil, G.S. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010, 11, 467-478. [CrossRef] [PubMed]
44. Czaja, M.J.; Ding, W.X.; Donohue, T.M., Jr.; Friedman, S.L.; Kim, J.S.; Komatsu, M.; Lemasters, J.J.; Lemoine, A.; Lin, J.D.; Ou, J.H.; et al. Functions of autophagy in normal and diseased liver. Autophagy 2013, 9, 1131-1158. [CrossRef] [PubMed]
45. Yang, S.; Wang, X.; Contino, G.; Liesa, M.; Sahin, E.; Ying, H.; Bause, A.; Li, Y.; Stommel, J.M.; Dell'antonio, G.; et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011, 25, 717-729. [CrossRef] [PubMed]
46. Yue, Z.; Jin, S.; Yang, C.; Levine, A.J.; Heintz, N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. USA 2003, 100, 15077-15082. [CrossRef] [PubMed]
47. Qu, X.; Yu, J.; Bhagat, G.; Furuya, N.; Hibshoosh, H.; Troxel, A.; Rosen, J.; Eskelinen, E.L.; Mizushima, N.; Ohsumi, Y.; et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Investig. 2003, 112, 1809-1820. [CrossRef] [PubMed]
48. Kuma, A.; Hatano, M.; Matsui, M.; Yamamoto, A.; Nakaya, H.; Yoshimori, T.; Ohsumi, Y.; Tokuhisa, T.; Mizushima, N. The role of autophagy during the early neonatal starvation period. Nature 2004, 432, 1032-1036. [CrossRef] [PubMed]
49. Itakura, E.; Mizushima, N. p62 Targeting to the autophagosome formation site requires self-oligomerization but not LC3 binding. J. Cell Biol. 2011, 192, 17-27. [CrossRef] [PubMed]
50. Johansen, T.; Lamark, T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011, 7, 279-296. [CrossRef] [PubMed]
51. Gan, N.; Sun, X.; Song, L. Activation of Nrf2 by microcystin-LR provides advantages for liver cancer cell growth. Chem. Res. Toxicol. 2010, 23, 1477-1484. [CrossRef] [PubMed]
52. Mathew, R.; Karp, C.M.; Beaudoin, B.; Vuong, N.; Chen, G.; Chen, H.Y.; Bray, K.; Reddy, A.; Bhanot, G.; Gelinas, C.; et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009, 137, 1062-1075. [CrossRef] [PubMed]
53. Chen, S.; Rehman, S.K.; Zhang, W.; Wen, A.; Yao, L.; Zhang, J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim. Biophys. Acta 2010, 1806, 220-229. [CrossRef] [PubMed]
54. Eskelinen, E.L. The dual role of autophagy in cancer. Curr. Opin. Pharmacol. 2011, 11, 294-300. [CrossRef] [PubMed]
55. Morselli, E.; Galluzzi, L.; Kepp, O.; Vicencio, J.M.; Criollo, A.; Maiuri, M.C.; Kroemer, G. Anti-and pro-tumor functions of autophagy. Biochim. Biophys. Acta 2009, 1793, 1524-1532. [CrossRef] [PubMed]
56. Yang, J.D.; Seol, S.Y.; Leem, S.H.; Kim, Y.H.; Sun, Z.; Lee, J.S.; Thorgeirsson, S.S.; Chu, I.S.; Roberts, L.R.; Kang, K.J. Genes associated with recurrence of hepatocellular carcinoma: Integrated analysis by gene expression and methylation profiling. J. Korean Med. Sci. 2011, 26, 1428-1438. [CrossRef] [PubMed]
57. Kim, J.H.; Kim, H.Y.; Lee, Y.K.; Yoon, Y.S.; Xu, W.G.; Yoon, J.K.; Choi, S.E.; Ko, Y.G.; Kim, M.J.; Lee, S.J.; et al. Involvement of mitophagy in oncogenic K-Ras-induced transformation: Overcoming a cellular energy deficit from glucose deficiency. Autophagy 2011, 7, 1187-1198. [CrossRef] [PubMed]
58. Lum, J.J.; Bauer, D.E.; Kong, M.; Harris, M.H.; Li, C.; Lindsten, T.; Thompson, C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120, 237-248. [CrossRef] [PubMed]
59. Degenhardt, K.; Mathew, R.; Beaudoin, B.; Bray, K.; Anderson, D.; Chen, G.; Mukherjee, C.; Shi, Y.; Gelinas, C.; Fan, Y.; et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006, 10, 51-64. [CrossRef] [PubMed]
60. Villanueva, A.; Hernandez-Gea, V.; Llovet, J.M. Medical therapies for hepatocellular carcinoma: A critical view of the evidence. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 34-42. [CrossRef] [PubMed]
61. Cook, K.L.; Shajahan, A.N.; Clarke, R. Autophagy and endocrine resistance in breast cancer. Expert Rev. Anticancer Ther. 2011, 11, 1283-1294. [CrossRef] [PubMed]
62. Kaza, N.; Kohli, L.; Roth, K.A. Autophagy in brain tumors: A new target for therapeutic intervention. Brain Pathol. 2012, 22, 89-98. [CrossRef] [PubMed]
63. Pandey, S.; Chandravati. Autophagy in cervical cancer: An emerging therapeutic target. Asian Pac. J. Cancer Prev. APJCP 2012, 13, 4867-4871. [CrossRef] [PubMed]
64. Osman, N.A.; Abd El-Rehim, D.M.; Kamal, I.M. Defective Beclin-1 and elevated hypoxia-inducible factor (HIF)-1α expression are closely linked to tumorigenesis, differentiation, and progression of hepatocellular carcinoma. Tumour Biol. 2015. [CrossRef] [PubMed]
65. Ding, Z.B.; Shi, Y.H.; Zhou, J.; Qiu, S.J.; Xu, Y.; Dai, Z.; Shi, G.M.; Wang, X.Y.; Ke, A.W.; Wu, B.; et al. Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res. 2008, 68, 9167-9175. [CrossRef] [PubMed]
66. Kotsafti, A.; Farinati, F.; Cardin, R.; Cillo, U.; Nitti, D.; Bortolami, M. Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. BMC Gastroenterol. 2012, 12, 118. [CrossRef] [PubMed]
67. Wu, W.Y.; Kim, H.; Zhang, C.L.; Meng, X.L.; Wu, Z.S. Clinical significance of autophagic protein LC3 levels and its correlation with XIAP expression in hepatocellular carcinoma. Med. Oncol. 2014, 31, 108. [CrossRef] [PubMed]
68. Xi, S.Y.; Lu, J.B.; Chen, J.W.; Cao, Y.; Luo, R.Z.; Wu, Q.L.; Cai, M.Y. The "stone-like" pattern of LC3A expression and its clinicopathologic significance in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2013, 431, 760-766. [CrossRef] [PubMed]
69. Toshima, T.; Shirabe, K.; Matsumoto, Y.; Yoshiya, S.; Ikegami, T.; Yoshizumi, T.; Soejima, Y.; Ikeda, T.; Maehara, Y. Autophagy enhances hepatocellular carcinoma progression by activation of mitochondrial β-oxidation. J. Gastroenterol. 2014, 49, 907-916. [CrossRef] [PubMed]
70. Wu, D.H.; Jia, C.C.; Chen, J.; Lin, Z.X.; Ruan, D.Y.; Li, X.; Lin, Q.; Min, D.; Ma, X.K.; Wan, X.B.; et al. Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma. Tumour Biol. 2014, 35, 12225-12233. [CrossRef] [PubMed]
71. Huang, G.M.; Jiang, Q.H.; Cai, C.; Qu, M.; Shen, W. SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway. Cancer Lett. 2015, 358, 180-190. [CrossRef] [PubMed]
72. Lu, G.D.; Ang, Y.H.; Zhou, J.; Tamilarasi, J.; Yan, B.; Lim, Y.C.; Srivastava, S.; Salto-Tellez, M.; Hui, K.M.; Shen, H.M.; et al. CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma. Hepatology 2015, 61, 965-978. [CrossRef] [PubMed]
73. Liu, C.; Xia, Y.; Jiang, W.; Liu, Y.; Yu, L. Low expression of GABARAPL1 is associated with a poor outcome for patients with hepatocellular carcinoma. Oncol. Rep. 2014, 31, 2043-2048. [CrossRef] [PubMed]
74. Xu, H.; Yu, H.; Zhang, X.; Shen, X.; Zhang, K.; Sheng, H.; Dai, S.; Gao, H. UNC51-like kinase 1 as a potential prognostic biomarker for hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 2013, 6, 711-717. [PubMed]
75. Luo, T.; Fu, J.; Xu, A.; Su, B.; Ren, Y.; Li, N.; Zhu, J.; Zhao, X.; Dai, R.; Cao, J.; et al. PSMD10/Gankyrin Induces Autophagy to Promote Tumor Progression through Cytoplasmic Interaction with ATG7 and Nuclear Transactivation of ATG7 Expression. Autophagy 2015. [CrossRef] [PubMed]
76. Cao, Y.; Klionsky, D.J. Physiological functions of Atg6/Beclin 1: A unique autophagy-related protein. Cell Res. 2007, 17, 839-849. [CrossRef] [PubMed]
77. Sun, Q.; Fan, W.; Zhong, Q. Regulation of Beclin 1 in autophagy. Autophagy 2009, 5, 713-716. [CrossRef] [PubMed]
78. Itakura, E.; Mizushima, N. Atg14 and UVRAG: Mutually exclusive subunits of mammalian Beclin 1-PI3K complexes. Autophagy 2009, 5, 534-536. [CrossRef] [PubMed]
79. Itakura, E.; Kishi, C.; Inoue, K.; Mizushima, N. Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol. Biol. Cell 2008, 19, 5360-5372. [CrossRef] [PubMed]
80. Takahashi, Y.; Coppola, D.; Matsushita, N.; Cualing, H.D.; Sun, M.; Sato, Y.; Liang, C.; Jung, J.U.; Cheng, J.Q.; Mule, J.J.; et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat. Cell Biol. 2007, 9, 1142-1151. [CrossRef] [PubMed]
81. Matsunaga, K.; Saitoh, T.; Tabata, K.; Omori, H.; Satoh, T.; Kurotori, N.; Maejima, I.; Shirahama-Noda, K.; Ichimura, T.; Isobe, T.; et al. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat. Cell Biol. 2009, 11, 385-396. [CrossRef] [PubMed]
82. Pattingre, S.; Tassa, A.; Qu, X.; Garuti, R.; Liang, X.H.; Mizushima, N.; Packer, M.; Schneider, M.D.; Levine, B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122, 927-939. [CrossRef] [PubMed]
83. Liang, X.H.; Jackson, S.; Seaman, M.; Brown, K.; Kempkes, B.; Hibshoosh, H.; Levine, B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402, 672-676. [PubMed]
84. Wan, X.B.; Fan, X.J.; Chen, M.Y.; Xiang, J.; Huang, P.Y.; Guo, L.; Wu, X.Y.; Xu, J.; Long, Z.J.; Zhao, Y.; et al. Elevated Beclin 1 expression is correlated with HIF-1α in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy 2010, 6, 395-404. [CrossRef] [PubMed]
85. Yu, M.; Gou, W.F.; Zhao, S.; Xiao, L.J.; Mao, X.Y.; Xing, Y.N.; Takahashi, H.; Takano, Y.; Zheng, H.C. Beclin 1 expression is an independent prognostic factor for gastric carcinomas. Tumour Biol. 2013, 34, 1071-1083. [CrossRef] [PubMed]
86. Giatromanolaki, A.; Koukourakis, M.I.; Koutsopoulos, A.; Chloropoulou, P.; Liberis, V.; Sivridis, E. High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. Gynecol. Oncol. 2011, 123, 147-151. [CrossRef] [PubMed]
87. Tanida, I.; Tanida-Miyake, E.; Ueno, T.; Kominami, E. The human homolog of Saccharomyces cerevisiae Apg7p is a Protein-activating enzyme for multiple substrates including human Apg12p, GATE-16, GABARAP, and MAP-LC3. J. Biol. Chem. 2001, 276, 1701-1706. [CrossRef] [PubMed]
88. Giatromanolaki, A.; Koukourakis, M.I.; Harris, A.L.; Polychronidis, A.; Gatter, K.C.; Sivridis, E. Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. J. Clin. Pathol. 2010, 63, 867-872. [CrossRef] [PubMed]
89. Fujii, S.; Mitsunaga, S.; Yamazaki, M.; Hasebe, T.; Ishii, G.; Kojima, M.; Kinoshita, T.; Ueno, T.; Esumi, H.; Ochiai, A. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 2008, 99, 1813-1819. [CrossRef] [PubMed]
90. Zhu, W.; Pan, X.; Li, F.; Zhang, Y.; Lu, X. Expression of Beclin 1 and LC3 in FIGO stage I-II cervical squamous cell carcinoma and relationship to survival. Tumor Biol. 2012, 33, 1653-1659. [CrossRef] [PubMed]
91. Huang, X.; Bai, H.M.; Chen, L.; Li, B.; Lu, Y.C. Reduced expression of LC3B-II and Beclin 1 in glioblastoma multiforme indicates a down-regulated autophagic capacity that relates to the progression of astrocytic tumors. J. Clin. Neurosci. 2010, 17, 1515-1519. [CrossRef] [PubMed]
92. Jiang, S.; Li, Y.; Zhu, Y.H.;Wu, X.Q.; Tang, J.; Li, Z.; Feng, G.K.; Deng, R.; Li, D.D.; Luo, R.Z.; et al. Intensive expression of UNC-51-like kinase 1 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Sci. 2011, 102, 1568-1575. [CrossRef] [PubMed]
93. Tang, J.; Deng, R.; Luo, R.Z.; Shen, G.P.; Cai, M.Y.; Du, Z.M.; Jiang, S.; Yang, M.T.; Fu, J.H.; Zhu, X.F. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res. Treat. 2012, 134, 549-560. [CrossRef] [PubMed]
94. Le Grand, J.N.; Chakrama, F.Z.; Seguin-Py, S.; Fraichard, A.; Delage-Mourroux, R.; Jouvenot, M.; Boyer-Guittaut, M. GABARAPL1 (GEC1): Original or copycat? Autophagy 2011, 7, 1098-1107. [PubMed]
95. Chakrama, F.Z.; Seguin-Py, S.; Le Grand, J.N.; Fraichard, A.; Delage-Mourroux, R.; Despouy, G.; Perez, V.; Jouvenot, M.; Boyer-Guittaut, M. GABARAPL1 (GEC1) associates with autophagic vesicles. Autophagy 2010, 6, 495-505. [CrossRef] [PubMed]
96. Berthier, A.; Seguin, S.; Sasco, A.J.; Bobin, J.Y.; de Laroche, G.; Datchary, J.; Saez, S.; Rodriguez-Lafrasse, C.; Tolle, F.; Fraichard, A.; et al. High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer. Br. J. Cancer 2010, 102, 1024-1031. [CrossRef] [PubMed]
97. Ntambi, J.M.; Miyazaki, M. Recent insights into stearoyl-CoA desaturase-1. Curr. Opin. Lipidol. 2003, 14, 255-261. [CrossRef] [PubMed]
98. Tan, S.H.; Shui, G.; Zhou, J.; Shi, Y.; Huang, J.; Xia, D.; Wenk, M.R.; Shen, H.M. Critical role of SCD1 in autophagy regulation via lipogenesis and lipid rafts-coupled AKT-FOXO1 signaling pathway. Autophagy 2014, 10, 226-242. [CrossRef] [PubMed]
99. Schuster, M.B.; Porse, B.T. C/EBPα: A tumour suppressor in multiple tissues? Biochim. Biophys. Acta 2006, 1766, 88-103. [CrossRef] [PubMed]
100. Matsusue, K.; Gavrilova, O.; Lambert, G.; Brewer, H.B., Jr.;Ward, J.M.; Inoue, Y.; LeRoith, D.; Gonzalez, F.J. Hepatic CCAAT/enhancer binding protein α mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice. Mol. Endocrinol. 2004, 18, 2751-2764. [CrossRef] [PubMed]
101. Lu, G.D.; Leung, C.H.; Yan, B.; Tan, C.M.; Low, S.Y.; Aung, M.O.; Salto-Tellez, M.; Lim, S.G.; Hooi, S.C. C/EBPα is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology 2010, 139, 632-643. [CrossRef] [PubMed]
102. Mayer, R.J.; Fujita, J. Gankyrin, the 26 S proteasome, the cell cycle and cancer. Biochem. Soc. Trans. 2006, 34, 746-748. [CrossRef] [PubMed]
103. Higashitsuji, H.; Itoh, K.; Nagao, T.; Dawson, S.; Nonoguchi, K.; Kido, T.; Mayer, R.J.; Arii, S.; Fujita, J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 2000, 6, 96-99. [PubMed]
104. Fu, J.; Chen, Y.; Cao, J.; Luo, T.; Qian, Y.W.; Yang, W.; Ren, Y.B.; Su, B.; Cao, G.W.; Yang, Y.; et al. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways. Hepatology 2011, 53, 181-192. [CrossRef] [PubMed]
105. Ni, H.M.; Williams, J.A.; Yang, H.; Shi, Y.H.; Fan, J.; Ding, W.X. Targeting autophagy for the treatment of liver diseases. Pharmacol. Res. 2012, 66, 463-474. [CrossRef] [PubMed]
106. Zhi, X.; Zhong, Q. Autophagy in cancer. F1000prime Rep. 2015, 7, 18. [CrossRef] [PubMed]
107. Guo, X.L.; Li, D.; Hu, F.; Song, J.R.; Zhang, S.S.; Deng, W.J.; Sun, K.; Zhao, Q.D.; Xie, X.Q.; Song, Y.J.; et al. Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells. Cancer Lett. 2012, 320, 171-179. [CrossRef] [PubMed]
108. Shimizu, S.; Takehara, T.; Hikita, H.; Kodama, T.; Tsunematsu, H.; Miyagi, T.; Hosui, A.; Ishida, H.; Tatsumi, T.; Kanto, T.; et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int. J. Cancer 2012, 131, 548-557. [CrossRef] [PubMed]
109. Shi, Y.H.; Ding, Z.B.; Zhou, J.; Hui, B.; Shi, G.M.; Ke, A.W.; Wang, X.Y.; Dai, Z.; Peng, Y.F.; Gu, C.Y.; et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 2011, 7, 1159-1172. [CrossRef] [PubMed]
110. Kota, J.; Chivukula, R.R.; O'Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.W.; Chang, T.C.; Vivekanandan, P.; Torbenson, M.; Clark, K.R.; et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137, 1005-1017. [CrossRef] [PubMed]
111. Gailhouste, L.; Ochiya, T. Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma. Histol. Histopathol. 2013, 28, 437-451. [PubMed]
112. Chang, Y.; Yan, W.; He, X.; Zhang, L.; Li, C.; Huang, H.; Nace, G.; Geller, D.A.; Lin, J.; Tsung, A. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology 2012, 143, 177-187. [CrossRef] [PubMed]
113. Luo, Z.; Yu, G.; Lee, H.W.; Li, L.; Wang, L.; Yang, D.; Pan, Y.; Ding, C.; Qian, J.; Wu, L.; et al. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res. 2012, 72, 3360-3371. [CrossRef] [PubMed]
114. Chen, L.H.; Loong, C.C.; Su, T.L.; Lee, Y.J.; Chu, P.M.; Tsai, M.L.; Tsai, P.H.; Tu, P.H.; Chi, C.W.; Lee, H.C.; et al. Autophagy inhibition enhances apoptosis triggered by BO-1051, an N-mustard derivative, and involves the ATM signaling pathway. Biochem. Pharmacol. 2011, 81, 594-605. [CrossRef] [PubMed]
115. Zou, M.; Lu, N.; Hu, C.; Liu, W.; Sun, Y.; Wang, X.; You, Q.; Gu, C.; Xi, T.; Guo, Q. Beclin 1-mediated autophagy in hepatocellular carcinoma cells: Implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling. Cell Signal. 2012, 24, 1722-1732. [CrossRef] [PubMed]
116. Kanzawa, T.; Kondo, Y.; Ito, H.; Kondo, S.; Germano, I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003, 63, 2103-2108. [PubMed]
117. Kim, E.H.; Sohn, S.; Kwon, H.J.; Kim, S.U.; Kim, M.J.; Lee, S.J.; Choi, K.S. Sodium selenite induces superoxide-mediated mitochondrial damage and subsequent autophagic cell death in malignant glioma cells. Cancer Res. 2007, 67, 6314-6324. [CrossRef] [PubMed]
118. Dupere-Richer, D.; Kinal, M.; Menasche, V.; Nielsen, T.H.; Del Rincon, S.; Pettersson, F.; Miller, W.H., Jr. Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance. Cell Death Dis. 2013, 4, e486. [CrossRef] [PubMed]
119. Yap, T.A.; Garrett, M.D.; Walton, M.I.; Raynaud, F.; de Bono, J.S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises. Curr. Opin. Pharmacol. 2008, 8, 393-412. [CrossRef] [PubMed]
120. Sieghart, W.; Fuereder, T.; Schmid, K.; Cejka, D.; Werzowa, J.; Wrba, F.; Wang, X.; Gruber, D.; Rasoul-Rockenschaub, S.; Peck-Radosavljevic, M.; et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007, 83, 425-432. [CrossRef] [PubMed]
121. Villanueva, A.; Chiang, D.Y.; Newell, P.; Peix, J.; Thung, S.; Alsinet, C.; Tovar, V.; Roayaie, S.; Minguez, B.; Sole, M.; et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008, 135, 1972-1983. [CrossRef] [PubMed]
122. Decaens, T.; Luciani, A.; Itti, E.; Hulin, A.; Roudot-Thoraval, F.; Laurent, A.; Zafrani, E.S.; Mallat, A.; Duvoux, C. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig. Liver Dis. 2012, 44, 610-616. [CrossRef] [PubMed]
123. Toso, C.; Merani, S.; Bigam, D.L.; Shapiro, A.M.; Kneteman, N.M. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010, 51, 1237-1243. [CrossRef] [PubMed]
124. Huynh, H.; Chow, K.H.; Soo, K.C.; Toh, H.C.; Choo, S.P.; Foo, K.F.; Poon, D.; Ngo, V.C.; Tran, E. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J. Cell. Mol. Med. 2009, 13, 1371-1380. [CrossRef] [PubMed]
125. Zhu, A.X.; Kudo, M.; Assenat, E.; Cattan, S.; Kang, Y.K.; Lim, H.Y.; Poon, R.T.; Blanc, J.F.; Vogel, A.; Chen, C.L.; et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA 2014, 312, 57-67. [CrossRef] [PubMed]
126. Thomas, H.E.; Mercer, C.A.; Carnevalli, L.S.; Park, J.; Andersen, J.B.; Conner, E.A.; Tanaka, K.; Matsutani, T.; Iwanami, A.; Aronow, B.J.; et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci. Transl. Med. 2012, 4, 139ra184. [CrossRef]
127. Egan, D.F.; Chun, M.G.; Vamos, M.; Zou, H.; Rong, J.; Miller, C.J.; Lou, H.J.; Raveendra-Panickar, D.; Yang, C.C.; Sheffler, D.J.; et al. Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. Mol. Cell 2015, 59, 285-297. [PubMed]
128. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378-390. [PubMed]
129. Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10, 25-34. [CrossRef]
130. Gauthier, A.; Ho, M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol. Res. 2013, 43, 147-154. [CrossRef] [PubMed]
131. Manov, I.; Pollak, Y.; Broneshter, R.; Iancu, T.C. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib-The role of extracellular signal-regulated kinase counteraction. FEBS J. 2011, 278, 3494-3507. [CrossRef] [PubMed]